Welcome to our dedicated page for Beam Therapeutics news (Ticker: BEAM), a resource for investors and traders seeking the latest updates and insights on Beam Therapeutics stock.
Beam Therapeutics Inc. (BEAM) is a pioneering biotechnology company developing precision genetic medicines through its innovative base editing platform. This page serves as the definitive source for official company announcements, clinical trial updates, and strategic developments in gene editing technology.
Investors and researchers will find curated press releases covering therapeutic advancements, financial disclosures, and scientific partnerships. Our collection includes updates on BEAM's hematology programs, in vivo editing initiatives, and manufacturing capabilities - all essential for understanding the company's position in genetic medicine.
Key content categories include clinical trial progress for sickle cell disease therapies, intellectual property developments in base editing, and strategic collaborations advancing CRISPR-based treatments. Each update is carefully verified to ensure accuracy and compliance with financial reporting standards.
Bookmark this page for direct access to Beam Therapeutics' latest milestones in creating single-edit genetic therapies. Check regularly for authoritative updates on one of biotechnology's most promising precision medicine platforms.
Beam Therapeutics (Nasdaq: BEAM) has appointed Chirfi Guindo, chief marketing officer of Human Health at Merck & Co., to its board of directors. Guindo brings over 25 years of pharmaceutical industry experience, having held senior executive roles in global strategy and commercial operations. Currently serving as chief marketing officer of Human Health at Merck, he leads the development and implementation of long-term strategy for the company's Human Health portfolio. Prior to his current role, Guindo served as executive vice president at Biogen and held various leadership positions at Merck in finance, sales, commercial, and marketing roles across multiple regions.
Beam Therapeutics (Nasdaq: BEAM), a biotechnology company focused on developing precision genetic medicines through base editing, has announced its participation in the 2024 Jefferies London Healthcare Conference. John Evans, CEO of Beam, will participate in a fireside chat on Tuesday, November 19, 2024, at 10:00 a.m. GMT in London. The presentation will be accessible via live webcast in the investor section of Beam's website and will remain archived for 60 days afterward.
Beam Therapeutics announced multiple presentations at the ASH Annual Meeting, including first clinical data from its BEAM-101 program for sickle cell disease. Initial results from the BEACON Phase 1/2 trial showed promising safety profile and efficacy in treated patients, with rapid fetal hemoglobin induction and sickle hemoglobin reduction. The company also presented positive preclinical data for its ESCAPE program, demonstrating successful non-genotoxic antibody-based conditioning in non-human primates. Additionally, preliminary data from the BEAM-201 trial showed complete response in 2 of 3 patients treated for T-cell lymphoblastic conditions.
Beam Therapeutics reported Q3 2024 financial results and program updates. The company has enrolled 35 patients and dosed eight in the BEACON Phase 1/2 trial of BEAM-101 for sickle cell disease. Initial clinical data will be presented at the upcoming ASH Annual Meeting. The first cohort dosing is completed for BEAM-302 in Alpha-1 Antitrypsin Deficiency, with data expected in 2025.
Financial highlights include $925.8M in cash and equivalents, with runway into 2027. Q3 net loss was $96.7M ($1.17 per share), with R&D expenses at $94.3M and G&A expenses at $26.5M. The company nominated development candidates BEAM-103 and BEAM-104 for its ESCAPE technology.
Beam Therapeutics (Nasdaq: BEAM) announced it will host a conference call and webcast on November 5, 2024, at 8:30 a.m. ET to discuss its third quarter 2024 financial results. The company will also review abstracts accepted for presentation at the 66th Annual Meeting of the American Society for Hematology (ASH). A live webcast will be available on the company's website, with a replay accessible for 60 days following the presentation.
Beam Therapeutics (Nasdaq: BEAM) reported significant progress in its clinical portfolio for Q2 2024. Key highlights include:
1. FDA clearance of IND for BEAM-301 in GSDIa
2. Over 20 patients enrolled and 6 dosed in BEACON Phase 1/2 trial of BEAM-101 for sickle cell disease
3. First patient dosed in Phase 1/2 trial of BEAM-302 for AATD
4. $1.0 billion in cash, with runway into 2027
The company submitted initial clinical data for BEAM-101 and preclinical data for ESCAPE to ASH. Beam expects to report initial BEAM-302 clinical data in 2025 and commence BEAM-301 patient dosing in early 2025. Q2 financial results show R&D expenses of $87.0 million and a net loss of $91.1 million ($1.11 per share).
Beam Therapeutics (Nasdaq: BEAM), a biotechnology company focused on precision genetic medicines through base editing, has announced the departure of its Chief Financial Officer, Terry-Ann Burrell, effective August 9, 2024. Burrell is leaving to pursue a new opportunity as vice chairman of investment banking at JPMorgan Chase. The company has initiated a search for her successor.
CEO John Evans praised Burrell's contributions over her five-year tenure, highlighting her role in the company's IPO, finance and corporate affairs development, and organizational growth. Burrell expressed confidence in Beam's future, citing its robust pipeline, including three recently launched clinical trials, strong balance sheet, and leadership team.
Beam Therapeutics announced the dosing of the first patient in its Phase 1/2 study for BEAM-302, a gene-editing treatment aimed at correcting the genetic cause of severe alpha-1 antitrypsin deficiency (AATD). The study will evaluate BEAM-302's safety, pharmacodynamics, pharmacokinetics, and efficacy. BEAM-302 aims to correct the PiZ allele, the prevalent variant causing AATD. The trial features dose escalation followed by dose expansion to find the optimal dose for future studies. This milestone represents significant progress for Beam and offers hope for AATD patients needing effective treatments.
Beam Therapeutics has released data highlighting an optimized and automated manufacturing process for BEAM-101, an investigational base-editing therapy for severe sickle cell disease (SCD).
This process, showcased at the European Hematology Association Hybrid Congress, integrates key technologies and automation improvements to optimize the production of CD34+ hematopoietic stem and progenitor cell (HSPC) genetic medicines.
The optimized process has shown robust and reproducible yields, with CD34+ purity between 84% and 95% and editing rates from 88% to 94% across multiple runs. BEAM-101 is currently undergoing Phase 1/2 clinical trials (BEACON).
This automation reduces the number of stem cell collections required, minimizes process duration and contamination risk, and increases cumulative yield and process consistency.
Beam's advancements aim to enhance product quality and patient experience in autologous cell and gene therapies for SCD.
Beam Therapeutics (BEAM), a biotech firm specializing in precision genetic medicines through base editing, announced its participation in the Jefferies Global Healthcare Conference. Giuseppe Ciaramella, President of Beam, will engage in a fireside chat on June 6, 2024, at 1:30 p.m. ET in New York City. The presentation will be webcasted live on Beam's investor website and archived for 60 days.
FAQ
What is the current stock price of Beam Therapeutics (BEAM)?
What is the market cap of Beam Therapeutics (BEAM)?
